New Zealand markets close in 2 hours 50 minutes

CLEARMIND MEDI.INC.O.N. (CWY0.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.0190+0.0140 (+1.39%)
At close: 03:29PM CEST
Full screen
Previous close1.0050
Open0.9940
Bid1.1140 x N/A
Ask1.1780 x N/A
Day's range0.9940 - 1.0190
52-week range0.8760 - 21.0000
Volume1,420
Avg. volume22
Market cap3.482M
Beta (5Y monthly)-1.66
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

    Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company previously announced the initiation of the last pre-clinical study required for a novel-food applicatio

  • GlobeNewswire

    Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

    The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed m

  • GlobeNewswire

    Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

    Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global right